lncRNAs and cyclin-dependent kinases: Unveiling their critical roles in cancer progression DOI

Raihan Siddique,

Lakshmi Thangavelu,

S RenukaJyothi

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 258, С. 155333 - 155333

Опубликована: Апрель 27, 2024

Язык: Английский

The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer DOI
Mohammed H. Abu-Alghayth, Farhan R. Khan, Tareg M. Belali

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 255, С. 155180 - 155180

Опубликована: Янв. 30, 2024

Язык: Английский

Процитировано

8

Chitosan and hyaluronic acid in breast cancer treatment: Anticancer efficacy and nanoparticle and hydrogel development DOI
Yanlin Jiang, Yu Cao, Yiqun Yao

и другие.

International Journal of Biological Macromolecules, Год журнала: 2025, Номер 301, С. 140144 - 140144

Опубликована: Янв. 21, 2025

Язык: Английский

Процитировано

1

Smart Mesoporous Silica Nanoparticles in Cancer: Diagnosis, Treatment, Immunogenicity, and Clinical Translation DOI Open Access
Satar Yousefiasl, Mahsa Ghovvati, Abbas Alibakhshi

и другие.

Small, Год журнала: 2025, Номер unknown

Опубликована: Янв. 22, 2025

Abstract In cancer research and personalized medicine, mesoporous silica nanoparticles (MSNs) have emerged as a significant breakthrough in both treatment diagnosis. MSNs offer targeted drug delivery, enhancing therapeutic effectiveness while minimizing adverse effects on healthy cells. Due to their unique characteristics, provide maximizing with minimal The review thoroughly investigates the role of potent carriers, noted for high drug‐loading capacity controlled release, which significantly improves permeability retention. Additionally, it discusses surface modification techniques that enable target cells precisely. manuscript provides comprehensive insights into various MSN applications, including diagnosis, design advanced biosensors, development conventional stimuli‐responsive delivery platforms. Special focus is given stimuli‐triggered systems, responsive internal stimuli (e.g., pH, redox, enzyme) external temperature, magnetic field, light, ultrasound), highlighting cutting‐edge progress technology. delves immunogenicity biosafety aspects MSNs, underscoring potential clinical translation. Besides summarizing current state oncology, this also illuminates path future advancements applications.

Язык: Английский

Процитировано

1

PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities DOI
Mohammed Ageeli Hakami, Ali Hazazi, Farhan R. Khan

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155019 - 155019

Опубликована: Дек. 7, 2023

Язык: Английский

Процитировано

20

Pollutants to pathogens: The role of heavy metals in modulating TGF-β signaling and lung cancer risk DOI
Asif Ahmad Bhat, Ehssan Moglad, Pooja Bansal

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 256, С. 155260 - 155260

Опубликована: Март 11, 2024

Язык: Английский

Процитировано

7

Targeting notch-related lncRNAs in cancer: Insights into molecular regulation and therapeutic potential DOI

Raihan Siddique,

Gaurav Gupta,

Johar MGM

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 257, С. 155282 - 155282

Опубликована: Апрель 1, 2024

Язык: Английский

Процитировано

7

Exploring ncRNA-mediated pathways in sepsis-induced pyroptosis DOI
Asif Ahmad Bhat, Yassine Riadi, Muhammad Afzal

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 256, С. 155224 - 155224

Опубликована: Фев. 23, 2024

Язык: Английский

Процитировано

6

Fabrication of folic acid-modified bovine serum albumin cloaked dual-drug loaded hollow mesoporous silica nanoparticles for pH-responsive and targeted delivery of gastric cancer therapy DOI Creative Commons
Yuan‐Wei Zhang,

Yuanxiao Liang

Heliyon, Год журнала: 2024, Номер 10(8), С. e29274 - e29274

Опубликована: Апрель 1, 2024

Combination therapy is a highly successful way to address the limitations of using single treatment method and improve therapy's overall efficacy. In this study, we developed unique hollow mesoporous silica nanoparticle (HMSN) coated with folic acid (FA)-modified bovine serum albumin (FA-BSA). This nanoparticle, referred as HFB, was designed target cancer cells release dual therapeutic drugs, Indocyanine green (ICG) Paclitaxel (PTX), in response specific stimuli termed HFB@IP. The BSA protein acts "gatekeeper" prevent early drug releases cargo leakage by detaching from reaction GSH. FA facilitates targeted transport into that express folate receptors (FR), enhancing effectiveness chemo-photodynamic (PDT). nanocarrier demonstrated vitro pH/redox-triggered HFB@IP due breaking imine bonds between aldehyde-functionalized HMSN (CHO-HMSN) FA-BSA disulfide bond inside BSA. addition, various biological assessments, including cell uptake experiments, effectively targets SGC-7901 induces apoptosis vitro. Further, it exhibits remarkable efficiency synergistically killing through therapy, indicated combination index (CI) 0.328. results showed combining biodegradable stimuli-responsive molecules could offer promising approach for precise treating gastric cancer, allowing controlled drugs necessary.

Язык: Английский

Процитировано

5

An insight on nanofibers assisted localized delivery of anti-cancer drugs to breast for an effective breast cancer treatment DOI
Shashank Chaturvedi, Vaibhav Rastogi, M. Aravind Kumar

и другие.

Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер 93, С. 105447 - 105447

Опубликована: Фев. 2, 2024

Язык: Английский

Процитировано

4

Targeting senescence and GATA4 in age-related cardiovascular disease: a comprehensive approach DOI
Mohd Imran, Abdulmalik Saleh Alfawaz Altamimi, Muhammad Afzal

и другие.

Biogerontology, Год журнала: 2025, Номер 26(1)

Опубликована: Янв. 20, 2025

Язык: Английский

Процитировано

0